Breaking News Instant updates and real-time market news.

AXNX

Axonics

$15.66

-0.36 (-2.25%)

, PVTL

Pivotal Software

$17.80

-0.23 (-1.28%)

18:59
12/11/18
12/11
18:59
12/11/18
18:59

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Axonics Modulation (AXNX) up 4.4%... Pivotal Software (PVTL) up 3.8%. ALSO HIGHER: Hain Celestical (HAIN) up 5.3% after disclosing that board formed a special committee to consider strategic alternatives... United Rentals (URI) up 3.1% after FY18, FY19 outlook at investor day... Viking Therapeutics (VKTX) up 1.6% after being initiated with Buy at B. Riley... First Solar (FSLR) up 1.2% after FY19 guidance... Jazz Pharma (JAZZ) up 1.2% after being initiated with Outperform at Oppenheimer... SEI Investments (SEIC) up 1.0% after increase to stock buyback... Resources (BEN) up 0.7% after raising dividend. DOWN AFTER EARNINGS: Dave & Busters (PLAY) down 15.1%... American Eagle Outfitters (AEO) down 5.4%... Arrowhead Pharma (ARWR) down 0.9%. ALSO LOWER: Marinus Pharma (MRNS) down 11.2% after equity offering... Fluidigm Corp (FLDM) down 6.2% after equity offering... Tocagen (TOCA) down 4.8% after equity offering... Gladstone Land Corp (LAND) down 4.7% after equity offering... Angi Homeservices (ANGI) down 3.2% after equity offering... Bank of America (BAC) down 0.5% after being downgraded to Market Perform at Keefe Bruyette... Morgan Stanley (MS) down 0.5% after being downgraded to Market Perform at Keefe Bruyette.

AXNX

Axonics

$15.66

-0.36 (-2.25%)

PVTL

Pivotal Software

$17.80

-0.23 (-1.28%)

HAIN

Hain Celestial

$18.80

-0.38 (-1.98%)

URI

United Rentals

$101.89

0.02 (0.02%)

VKTX

Viking Therapeutics

$9.47

0.01 (0.11%)

FSLR

First Solar

$42.43

-0.79 (-1.83%)

JAZZ

Jazz Pharmaceuticals

$140.46

0.9 (0.64%)

SEIC

SEI Investments

$48.50

-0.64 (-1.30%)

BEN

Franklin Resources

$31.53

-0.52 (-1.62%)

PLAY

Dave & Buster's

$51.08

-1.44 (-2.74%)

AEO

American Eagle

$19.03

-0.49 (-2.51%)

ARWR

Arrowhead

$13.61

-0.05 (-0.37%)

MRNS

Marinus Pharmaceuticals

$5.10

-0.14 (-2.67%)

FLDM

Fluidigm

$7.58

-0.11 (-1.43%)

TOCA

Tocagen

$12.85

0.2 (1.58%)

LAND

Gladstone Land

$13.33

-0.16 (-1.19%)

ANGI

Angi Homeservices

$16.62

-0.11 (-0.66%)

BAC

Bank of America

$24.58

-0.17 (-0.69%)

MS

Morgan Stanley

$40.62

-0.07 (-0.17%)

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 13

    Dec

  • 13

    Dec

  • 14

    Dec

  • 14

    Dec

  • 19

    Dec

  • 20

    Dec

  • 20

    Dec

  • 12

    Feb

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

AXNX Axonics
$15.66

-0.36 (-2.25%)

11/26/18
RHCO
11/26/18
INITIATION
Target $20
RHCO
Buy
Axonics initiated with a Buy at SunTrust
SunTrust analyst Bruce Nudell started Axonics with a Buy rating and $20 price target.
11/26/18
WELS
11/26/18
INITIATION
Target $22
WELS
Outperform
Axonics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Axonics (AXNX) with an Outperform rating and $22 price target. Historically, the sacral neuromodulationcategory has been a one-player market but he believes Axonics - when FDA approved - will be able to take share from Medtronic (MDT) and help catalyze broader SNM market growth and penetration.
11/26/18
11/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nvidia (NVDA) initiated with an Outperform at Credit Suisse. 2. Orchard Therapeutics (ORTX) initiated with an Outperform at Wedbush and Cowen, an Overweight at JPMorgan, and a Neutral at Goldman Sachs. 3. Twist Bioscience (TWST) initiated with an Outperform at Cowen and Baird as well as a Neutral at JPMorgan. 4. Axonics (AXNX) initiated with a Buy at BofA/Merrill and SunTrust, an Outperform at Wells Fargo, and an Overweight at Morgan Stanley. 5. Gamida Cell (GMDA) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/04/18
PIPR
12/04/18
NO CHANGE
Target $25
PIPR
Overweight
Nuvectra approval strategy validated by Axonics filing, says Piper Jaffray
Nuvectra (NVTR) competitor Axonics (AXNX) announced this morning that it has resubmitted a literature-based market approval application for its sacral neuromodulation device, which is different than recent commentary that it would be going down the traditional clearance pathway, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This approach for approval is the same as what Nuvectra is doing to get Virtis cleared and provides "further validation that this strategy is the appropriate one," the analyst adds. He continues to believe Nuvectra is attractive solely based on its spinal cord stimulation business prospects and views Virtis as "another leg of value creation." O'Brien encourages investors to build positions in the name and keeps an Overweight rating on the stock with a $25 price target.
PVTL Pivotal Software
$17.80

-0.23 (-1.28%)

10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
IBM deal reinforces Morgan Stanley confidence in Hybrid Cloud emergence
After IBM (IBM) announced its intention to acquire Red Hat (RHT) for about $34B in a deal with an over 60% premium to Red Hat's Friday closing price, Morgan Stanley analyst Keith Weiss said the announcement reinforced both his confidence in the emergence of Hybrid Cloud architectures and the strength of IT spending into 2019. Red Hat has been Microsoft's (MSFT) primary competitor within server operating systems, and has generally been taking share, said Weiss, who thinks the longer-term opportunity or threat for Microsoft hinges on the ability of IBM to execute well and maintain the open source enthusiasm around the Red Hat distributions. For VMware (VMW) and Pivotal Software (PVTL), while Weiss sees little near-term impact, he adds that the proposed combination would likely result in a fiercer competitive environment going forward. For New Relic (NEWR), he sees little direct competitive impacts from the proposed merger. Given HortonWorks' (HDP) strong existing ties to IBM, Cloudera (CLDR) could benefit by becoming a preferred data management vendor within the OpenShift ecosystem, Weiss added.
10/19/18
WEDB
10/19/18
INITIATION
Target $25
WEDB
Outperform
Pivotal Software initiated with an Outperform at Wedbush
Wedbush analyst Daniel Ives initiated Pivotal Software with an Outperform rating and $25 price target, telling investors in a research note that he believes the company is poised to benefit from the unprecedented digital disruption currently faced by enterprises over the long term. Despite the speed bump in Q2 with the billings miss that has put the company in the investor penalty box, Ives believes core fundamentals and the market opportunity for Pivotal remains healthy and in the medium term he believes the company has a long runway ahead of itself after navigating through this near-term billings volatility.
10/22/18
NEED
10/22/18
INITIATION
Target $25
NEED
Buy
Pivotal Software initiated with a Buy at Needham
Needham analyst Jack Andrews initiated Pivotal Software with a Buy and $25 price target.
10/23/18
NEED
10/23/18
INITIATION
NEED
Buy
Red Hat, Pivotal Software, ServiceNow initiated with a Buy at Needham
As reported earlier, Needham analyst Jack Andrews initiated Red Hat (RHT), Pivotal Software (PVTL), and ServiceNow (NOW) with Buy ratings as part of his broader research note on select cloud-driven infrastructure software companies. The analyst notes that he expects new proprietary applications to generate rapid growth of cloud-based workloads, making the "platform as a service", or PaaS, market "one of the fastest growing segments in the technology stack". Andrews also points out that in addition to allowing "enterprises to run machine learning and deep learning algorithms in order to glean insights on how to improve customer experiences", a unique characteristic of infrastructure software companies is their pricing model driven by "per compute" or "consumption basis". The analyst contends that this makes them an attractive investment as "an infrastructure software vendor can maintain a long tail of growth within an enterprise by continuing to add licenses". Andrews assigns Red Hat a price target of $183, Pivotal Software a target of $25, and ServiceNow a price target of $224.
HAIN Hain Celestial
$18.80

-0.38 (-1.98%)

11/09/18
UBSW
11/09/18
NO CHANGE
Target $21
UBSW
Sell
Hain Celestial back half guidance at risk, says UBS
UBS analyst Steven Strycula said the arrival of Hain Celestial's new CEO may eventually change the narrative on the shares, but he believes the next few quarters will be needed to upgrade the talent, reassess investment spending, and review the sensibility of the company's portfolio scope. Strycula remains cautious because of the risk of an earnings reset and reiterated his Sell rating while lowering his price target to $21 from $25 on Hain Celestial shares.
11/12/18
LOOP
11/12/18
NO CHANGE
Target $24
LOOP
Hold
Hain Celestial price target lowered to $24 from $29 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Hain Celestial to $24 after its Q1 results, saying the 36% decline in EBITDA amid "increased trade spending, higher costs, and supply disruptions was bigger than he expected". The analyst notes that the company's new CEO should start to "focus on marketing spending on the best opportunities" within its brand portfolio, but expects this to be a "multi-year process". Wolf adds that although consumption trends have showed signs of improving, he sees Hain Celestial's near-term risk-reward as "balanced", keeping his Hold rating.
10/12/18
PIPR
10/12/18
INITIATION
Target $26
PIPR
Neutral
Hain Celestial assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery assumed coverage of Hain Celestial with a Neutral rating and $26 price target. The analyst prefers better visibility on "sustainable top-line acceleration" before getting more constructive on the shares.
11/09/18
JEFF
11/09/18
NO CHANGE
Target $45
JEFF
Buy
Hain Celestial selloff yesterday a buying opportunity, says Jefferies
Jefferies analyst Akshay Jagdale attributes the selloff yesterday in shares of Hain Celestial to investor concerns of an earnings reset in February following the CEO's strategic review, especially "in light of the significant" second half improvement needed to meet fiscal 2019 guidance. The analyst estimates the market is pricing in 20% lower earnings than what management guiding to, or fiscal 2019 earnings per share in the range of 98c-$1.13 versus guidance of $1.21-$1.38. The analyst, however, views the concerns as overblown. The market seems to be of the view that Hain cannot simultaneously grow its sales and its margins over the long-term, Jagdale tells investors in a research note. He disagrees, however, and views yesterday's selloff as a buying opportunity. The analyst keeps a Buy rating on Hain Celestial with a $45 price target.
URI United Rentals
$101.89

0.02 (0.02%)

10/31/18
MSCO
10/31/18
NO CHANGE
Target $175
MSCO
Overweight
United Rentals shares 'too cheap to ignore,' says Morgan Stanley
Morgan Stanley analyst Courtney Yakavonis contends that United Rentals shares have become "too cheap to ignore" after falling nearly 45% since mid-September. She believes the market is underappreciating the potential for modest, but sustained, rate growth in 2019 as well as margin improvements. The stock is currently trading at a level typically only seen when United exhibits either negative organic revenue growth or during periods of declining non-residential growth, which is not the case, noted the investors. She maintains an Overweight rating on United Rentals shares with a $175 price target.
10/23/18
STPT
10/23/18
INITIATION
Target $140
STPT
Buy
United Rentals initiated with a Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas initiated United Rentals with a Buy and $140 price target.
11/15/18
UBSW
11/15/18
NO CHANGE
Target $180
UBSW
Buy
United Rentals on a path of higher returns and growth, says UBS
UBS analyst Steven Fisher met with United Rentals management and came away confident the company is on a path of driving higher returns and profitable growth over the longer-term. He said demand remains solid in the medium-term and the customer-facing strategy is working. Fisher reiterated his Buy rating and $180 price target on United Rentals shares.
10/22/18
NRCS
10/22/18
UPGRADE
Target $49
NRCS
Buy
Northcoast upgrades Herc Holdings to Buy on 'overdone' selloff
Northcoast analyst John Healy upgraded Herc Holdings (HRI) to Buy from Neutral with a $49 price target. The 45% decline in shares since the July highs are largely the result of a "de-risking macro trade" as well as "less than hoped for rate trends" at competitor United Rentals (URI), Healy told investors earlier in a research note. The analyst views the selloff as "overdone" and believes Herc will "impress" when reporting results with a positive outlook.
VKTX Viking Therapeutics
$9.47

0.01 (0.11%)

12/11/18
RILY
12/11/18
INITIATION
Target $16
RILY
Buy
Viking Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani started Viking Therapeutics with a Buy rating and $16 price target.
11/19/18
RAJA
11/19/18
UPGRADE
RAJA
Strong Buy
Viking Therapeutics upgraded to Strong Buy from Outperform at Raymond James
11/19/18
11/19/18
UPGRADE
Target $43

Strong Buy
Viking Therapeutics upgraded to Strong Buy at Raymond James
As previously reported, Raymond James upgraded Viking Therapeutics (VKTX) to Strong Buy from Outperform with a $43 price target. Following AASLD, Analyst Steven Seedhouse thinks TR-B remains one of the most promising mechanisms with proof-of-concept in NASH based on VK2809 and MGL-3196 data presented and conversations with physicians. The analyst expects increased comfort with Viking's path to market as we approach several catalysts including a long-term animal toxicology study completion, IND filing/acceptance, and Phase 2b start. Seedhouse also expects the M&A premium in Madrigal Pharmaceuticals (MDGL) to shift to Viking, which has a more attractive valuation if there is a rush on NASH assets.
11/19/18
11/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS with analyst Brennan Hawken saying he believes "misperceptions about late cycle risk" has created an attractive entry point for shares. 2. Helmerich & Payne (HP) upgraded two notches to Buy from Sell at SunTrust, to Buy from Neutral at Citi, and to Neutral from Underperform at Credit Suisse. 3. Viking Therapeutics (VKTX) upgraded to Strong Buy from Outperform at Raymond James with analyst Steven Seedhouse saying he thinks TR-B remains one of the most promising mechanisms with proof-of-concept in NASH based on VK2809 and MGL-3196 data presented and conversations with physicians. 4. Big Lots (BIG) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying he expects a "strong" tax refund season in early 2019 for lower/moderate-income families. 5. Booking Holdings (BKNG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Robert Coolbrith saying he believes current valuation offers a favorable entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FSLR First Solar
$42.43

-0.79 (-1.83%)

12/04/18
12/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Waste Management (WM) double upgraded to Buy from Sell at Goldman Sachs with analyst Brian Maguire saying given the age of the current business cycle and expectations for slowing economic growth, now is the right time to own Waste stocks. 2. RMR Group (RMR) upgraded to Buy from Neutral at B. Riley FBR with analyst Bryan Maher citing valuation. 3. Keurig Dr Pepper (KDP) upgraded to Outperform from Neutral at Macquarie. 4. First Solar (FSLR) upgraded to Buy from Hold at Argus with analyst David Coleman citing the company's position in the solar industry with "positive cash flow, solid balance sheet, and focus on cadmium telluride technology, which should provide a cost advantage relative to more commoditized technologies." 5. Sherwin-Williams (SHW) upgraded to Buy from Hold at Deutsche Bank with analyst Nishu Sood saying he believes the paths for housing construction and remodeling "could diverge," which leaves him preferring remodeling focused names versus new construction exposed names. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/18
ROTH
12/07/18
NO CHANGE
Target $65
ROTH
Buy
First Solar has 'clear path' to attractive cost structure, says Roth Capital
Roth Capital analyst Philip Shen maintained a Buy rating and $65 price target on First Solar ahead of its 2019 guidance call next week. In a research note to investors, Shen says checks suggest the company may be one quarter late in fully ramping up its first S6 facilities in Ohio and Malaysia, but key hurdles have been overcome and management has a "clear path" to reaching an attractive cost structure.
12/04/18
ARGS
12/04/18
UPGRADE
Target $60
ARGS
Buy
First Solar upgraded to Buy from Hold at Argus
As reported earlier, Argus analyst David Coleman upgraded First Solar to Buy from Hold with a price target of $60. The analyst cites the company's position in the solar industry with "positive cash flow, solid balance sheet, and focus on cadmium telluride technology, which should provide a cost advantage relative to more commoditized technologies." Coleman adds that First Solar shares have underperformed over the past 3 months with a 13% decline but believes that the stock is "attractively valued" at 15.5-times his expected forward earnings, which is in the lower half of its 4.5- to 37.7-times historical range.
12/04/18
ARGS
12/04/18
UPGRADE
ARGS
Buy
First Solar upgraded to Buy from Hold at Argus
JAZZ Jazz Pharmaceuticals
$140.46

0.9 (0.64%)

11/07/18
RBCM
11/07/18
NO CHANGE
Target $184
RBCM
Outperform
Jazz Pharmaceuticals price target lowered to $184 from $194 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Jazz Pharmaceuticals to $184 after its Q3 results, saying the company again "missed the mark" on Vyxeos whose launch continues to disappoint. The analyst keeps his Outperform rating on Jazz Pharmaceuticals, citing the "robust" 9% volume growth for Xyrem and its anticipated near-term launches, but believes that unlocking value for investors may take "longer than anticipated".
11/20/18
MZHO
11/20/18
NO CHANGE
Target $157
MZHO
Neutral
Jazz Pharmaceuticals price target lowered to $157 from $173 at Mizuho
Mizuho analyst Irina Koffler lowered her price target for Jazz Pharmaceuticals to $157 citing the company's "disappointing" quarter, "weak" commercial execution on newly launched Vyxeos, and "more persistent" Erwinaze supply disruption that is not expected to improve. The analyst keeps a Neutral rating on the shares.
11/27/18
RBCM
11/27/18
NO CHANGE
RBCM
RBC Capital likes select Specialty Pharma names on recent sector selling
RBC Capital analyst Randall Stanicky is positive on Amneal Pharmaceuticals (AMRX), Endo International (ENDP), Flexion Therapeutics (FLXN), Jazz Pharmaceuticals (JAZZ) as his top selections in Specialty Pharma, saying the sector has come under particular pressure in the most recent market sell-off. The analyst anticipates Amneal Pharmaceuticals to benefit from a cyclical generics recovery in the 2nd half of 2019, saying its "valuation is compelling against growth outlook". For Endo International, Stanicky sees the cellulite data driven selloff as overdone and believes that its low valuation helps to set a floor for the stock. For Flexion, the analyst anticipates a 2019 inflection on ramping Zilretta launch, adding that its 32% short interest is "hard to ignore". For Jazz Pharma, Stanicky points to a re-set of expectations around Vyxeos in Q3 as the company enters a "catalyst-heavy path led by December 20th solriamfetol PDUFA" and a material discount in valuation. The analyst maintain his Outperform rating on these four stocks.
12/11/18
OPCO
12/11/18
INITIATION
Target $180
OPCO
Outperform
Jazz Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer analyst Esther Rajavelu started Jazz Pharmaceuticals with an Outperform rating and $180 price target. The company has laid the groundwork to sustain its sleep franchise post Xyrem generics, Rajavelu tells investors in a research note. The analyst believes Jazz has a "solid" base business with its central nervous system-related sleep disorders franchise and a late-stage pipeline with "several" near-term catalysts.
SEIC SEI Investments
$48.50

-0.64 (-1.30%)

04/12/18
WBLR
04/12/18
DOWNGRADE
WBLR
Market Perform
SEI Investments downgraded to Market Perform from Outperform at William Blair
William Blair analyst Christopher Shutler downgraded SEI Investments to Market Perform on expectations the company will see "choppiness" related to private banks and markets.
10/24/18
KBWI
10/24/18
UPGRADE
Target $63
KBWI
Outperform
SEI Investments upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Robert Lee upgraded SEI Investments to Outperform while lowering his price target for the shares to $63 from $68. The analyst sees positive new business trends following the company's Q3 results and views the current valuation as attractive.
04/27/18
MZHO
04/27/18
NO CHANGE
MZHO
Buy
SEI Investments selloff yesterday overdone, says Mizuho
Mizuho analyst Thomas McCrohan views the selloff yesterday in shares of SEI Investments as overdone. The announced Wells implementation delay "is not a canary in the coal mine that foretells of impending danger ahead," McCrohan tells investors in a research note. He attributes the delay to specific circumstances at a single client. He believes no read-through conclusions should be made regarding other implementations and reiterates a Buy rating on SEI shares.
12/05/18
RSBL
12/05/18
INITIATION
Target $59
RSBL
Neutral
SEI Investments initiated with a Neutral at Rosenblatt
Rosenblatt analyst Kenneth Hill yesterday morning started SEI Investments with a Neutral rating and $59 price target.
BEN Franklin Resources
$31.53

-0.52 (-1.62%)

09/06/18
09/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Histogenics (HSGX) downgraded to Neutral from Buy at BTIG with analyst Ryan Zimmerman citing Histogenics announcement that its Phase 3 trial comparing NeoCart to microfracture surgery missed its primary endpoint. 2. Chevron (CVX) and ConocoPhillips (COP) were downgraded to Neutral from Buy at BofA/Merrill. 3. Franklin Resources (BEN) downgraded to Underweight from Neutral at JPMorgan with analyst Kenneth Worthington saying he believes the more recent weakness in emerging markets, and in particular in emerging market debt, will weigh on both Franklin's organic growth and earnings potential. 4. HealthEquity (HQY) downgraded to Neutral from Buy at BofA/Merrill with analyst Allen Lutz saying recent share strength fully discounts upside from interest rates and potential upside from a proposed Senate HSA bill that could add 10-15% to industry AUM. 5. Rio Tinto (RIO) downgraded to Hold from Buy at Investec. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/18
JPMS
09/06/18
DOWNGRADE
Target $29
JPMS
Underweight
JPMorgan downgrades Franklin Resources to Underweight with $29 price target
JPMorgan analyst Kenneth Worthington downgraded Franklin Resources to Underweight from Neutral and lowered his price target for the shares to $29 from $32. The analyst believes the more recent weakness in emerging markets, and in particular in emerging market debt, will weigh on both Franklin's organic growth and earnings potential. He thinks challenges in emerging markets put additional pressure on "an already challenging growth story characterized by weak fund performance, significant outflows, and declining margins." Worthington continues to have a negative view on the asset management sector.
09/06/18
09/06/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ANALYSTS WEIGH IN ON MICRON: Despite recent softness in DRAM spot pricing, the more appropriate metric for Micron Technology (MU) investors to focus on is gross margin, Deutsche Bank analyst Sidney Ho said. On gross margin, the analyst sees Micron benefiting from "solid cost improvement through technology transition" in fiscal 2019. Further, he believes the DRAM market has become more diverse, which should help offset temporary weakness in any given end market. As the company continues to execute on its technology roadmap and delivers solid operating results, Ho expects Micron's stock valuation to re-rate. He kept a Buy rating and $80 price target on Micron. However, Baird analyst Tristan Gerra said Micron is no longer a top large-cap idea, citing its valuation and the likelihood gross margins may be nearing their peak. He also noted DRAM pricing is likely peaking and NAND is in significant oversupply. Gerra maintained an Outperform rating but lowered his price target to $75 from $100 on Micron shares. ARGUS UPGRADES PG&E TO BUY: Argus analyst Jacob Kilstein upgraded PG&E (PCG) to Buy from Hold with a price target of $54, saying the company's recent California legislative victory will reduce its liability for last year's wildfire as its earnings outlook improves. Kilstein further anticipates PG&E to announce a timeline regarding its dividend reinstatement after being forced to suspend its quarterly payout on concerns about its potential wildfire damage responsibility estimated as high as $12B. NORTHLAND DOWNGRADES TILRAY TO MARKET PERFORM: Northland analyst Mike Grondahl downgraded Tilray (TLRY) to Market Perform from Outperform. While he continues to see the company playing a "huge role" in the recreational-use cannabis market in Canada and other countries and the medical market in Europe, he also believes the risk/reward is far more balanced following the recent "massive" move in the stock. JPMORGAN CUTS FRANKLIN RESOURCES TO UNDERWEIGHT: JPMorgan analyst Kenneth Worthington downgraded Franklin Resources (BEN) to Underweight from Neutral and lowered his price target for the shares to $29 from $32. The analyst believes the more recent weakness in emerging markets, and in particular in emerging market debt, will weigh on both Franklin's organic growth and earnings potential. He thinks challenges in emerging markets put additional pressure on "an already challenging growth story characterized by weak fund performance, significant outflows, and declining margins." Worthington continues to have a negative view on the asset management sector.
09/06/18
JPMS
09/06/18
DOWNGRADE
Target $29
JPMS
Underweight
Franklin Resources downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Kenneth Worthington downgraded Franklin Resources to Underweight and lowered his price target for the shares to $29 from $32.
PLAY Dave & Buster's
$51.08

-1.44 (-2.74%)

12/07/18
MAXM
12/07/18
NO CHANGE
Target $76
MAXM
Buy
Dave & Buster's price target raised to $76 from $71 at Maxim
Maxim analyst Stephen Anderson raised his price target on Dave & Buster's to $76 and kept his Buy rating ahead of its Q3 earnings next week. The analyst says his channel checks indicate that the company will launch a new virtual reality game - Dragon Frost - system-wide on December 17th, which will yield a "modest list" to its Amusement component sales. Anderson also anticipates Dave & Busters to return to its historical comp growth of 2%-3% in FY19-FY20.
12/04/18
JEFF
12/04/18
NO CHANGE
Target $72
JEFF
Buy
Dave & Buster's unit grow underappreciated, says Jefferies
After having recently met with Dave & Buster's management in Las Vegas, Jefferies analyst Andy Barish said he sees the company's virtual reality platform helping to drive sustained growth in FY19 and beyond. He also believes the company's 10%+ unit growth has been underappreciated, adding that he sees its pipeline filled out into 2020 and noting that its new stores continue to outperform. Following the meetings, Barish keeps a Buy rating and $72 price target on Dave & Buster's shares.
10/24/18
LOOP
10/24/18
INITIATION
Target $70
LOOP
Buy
Dave & Buster's initiated with a Buy at Loop Capital
Loop Capital analyst Lynne Collier initiated Dave & Buster's with a Buy rating and a price target of $70. The analyst expects the company's comps to positively inflect in Q4 thanks to its improved gaming content and also produce a double-digit unit growth over the next 5 or more years. Collier adds that the performance of the new units remains strong and the valuation on the stock at 9.0-times next-12-month EBITDA is in-line with its 5-year average.
12/11/18
LOOP
12/11/18
NO CHANGE
Target $70
LOOP
Buy
Dave & Buster's new fast casual concept is 'promising', says Loop Capital
Loop Capital analyst Lynne Collier kept her Buy rating and $70 price target on Dave & Buster's, saying her recent visit to its Dallas location to experience the new "fast casual/food truck concept named TNT Tacos" highlighted its impressive execution and promising potential. The analyst believes that this "successful addition" to Dave & Buster's experience will offer a more convenient dining alternative, adding to its incremental food/beverage sales. Collier maintains her view on the stock as one of her "favorite" names heading into 2019 and anticipates its comps to return to positive in Q4.
AEO American Eagle
$19.03

-0.49 (-2.51%)

10/19/18
SBSH
10/19/18
UPGRADE
Target $27
SBSH
Buy
Citi upgrades American Eagle to Buy on underappreciated Aerie concept
Citi analyst Paul Lejuez upgraded American Eagle Outfitters to Buy from Neutral with a $27 price target. The stock is down 30% since the Q2 earnings report on August 29, and the company "has recently been painted with the same brush" as most retail stocks, Lejuez tells investors in a research note. However, he believes American Eagle "has something that others don't - one of the most attractive growth concepts in retail," namely Aerie. Aerie is taking market share in the lingerie market with consistent double digit comps and significant growth potential, Lejuez contends. He believes the market is not giving American Eagle the credit it deserves for Aerie at current share levels.
11/01/18
BOFA
11/01/18
DOWNGRADE
Target $18
BOFA
Underperform
American Eagle downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst David Buckley downgraded American Eagle to Underperform from Neutral and cut its price target to $18 from $27 citing lack of margin improvement. Buckley thinks American Eagle brand comps have peaked and will trend to a low single digit growth rate in 2019, creating risk to current merchandising margins, noting the lack of pricing power. As a result, the analyst lowered American Eagle's FY19 earnings estimates to $1.45 from $1.64, versus consensus of $1.62.
11/26/18
DBAB
11/26/18
UPGRADE
Target $24
DBAB
Buy
American Eagle upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Tiffany Kanaga upgraded American Eagle Outfitters (AEO) to Buy with an unchanged price target of $24. The analyst also reiterates a Sell rating on Abercrombie & Fitch (ANF) ahead of the Q3 results for the teen retailers. The analyst views American Eagle's valuation as undemanding and sees a buying opportunity at current share levels. Amid more favorable weather and following Black Friday channel checks, the analyst has increased confidence that the company can exceed guidance in Q3 and cycle a tough compare in Q4.
11/27/18
WEDB
11/27/18
NO CHANGE
WEDB
Macy's, Target among engagement winners during holiday period, says Wedbush
Wedbush analyst Jen Redding notes that the U.S. holiday selling season has started off strong, with winning transactions becoming more important than where they occur, as e-commerce selling surged past expectations.The analyst examined his Campaign Tracker to study key marketing and performance indicators across retailers in the peak holiday selling period. Zara, Free People and Anthropologie (URBN), lululemon (LULU), aerie (AEO), Kohl's (KSS), Macy's (M), and Target (TGT) saw strong engagement for the key holiday period with engagement trends well-above respective sector averages, Redding contends.
ARWR Arrowhead
$13.61

-0.05 (-0.37%)

10/04/18
CANT
10/04/18
NO CHANGE
Target $24
CANT
Overweight
Arrowhead price target raised to $24 from $18 at Cantor Fitzgerald
Cantor Fitzgerald analyst Justin Kim raised his price target for Arrowhead (ARWR) to $24 from $18 following a newly announced collaboration and license agreement with Johnson & Johnson's (JNJ) subsidiary Janssen. Overall, the analyst feels the agreement is positive for the company as the support of a large partner could speed up the development timelines, increase market penetration with expertise, and validates the TRiM platform that Arrowhead uses. The additional cash will support Arrowhead's internal clinical development, he adds. Kim reiterates an Overweight rating on Arrowhead's shares.
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
11/12/18
PIPR
11/12/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead's new data validate TRiM pipeline, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes new data presented by Arrowhead (ARWR) at the AASLD meeting on ARO-AAT and ARO-HBV validate the company's proprietary TRiM platform. He expects a potentially registrational Phase 2/3 trial for ARO-AAT to start in the first quarter of 2019 and noted that partner Janssen (JNJ) intends to begin Phase 2 studies of ARO-HBV in the first half of next year. Tenthoff keeps an Overweight rating and $25 price target on Arrowhead shares.
10/17/18
PIPR
10/17/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead 25% pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Arrowhead Pharmaceuticals with a $25 price target following yesterday's R&D day. The analyst is a buyer on recent weakness with the stock down 25% since announcing the Janssen deal earlier this month. Arrowhead now trades at a market capitalization of $1.27B with pro forma cash of $328M to advance its wholly-owned RNAi pipeline, Tenthoff tells investors in a research note. He points out the company will give an oral presentation on ARO-AAT including Phase I safety and serum Alpha-1 Antitrypsin levels in healthy volunteers in a late-breaker at the annual American Association for the study of Liver Diseases meeting on November 12.
MRNS Marinus Pharmaceuticals
$5.10

-0.14 (-2.67%)

07/19/18
MZHO
07/19/18
NO CHANGE
Target $13
MZHO
Buy
Marinus can rally 100% on postpartum depression data, says Mizuho
Mizuho analyst Difei Yang believes Marinus Pharmaceuticals' Q3 top-line data from part 1 of the Phase 2 Magnolia study of ganaxolone IV in women with postpartum depression will be an "important catalyst" for the shares. The analyst sees upside potential of 100%-plus, assuming "convincing data including a clear dose response." She believes the downside is limited given the history of the compound and potential in other indications. Yang reiterates a Buy rating on Marinus with a $13 price target.
07/02/18
CANT
07/02/18
INITIATION
Target $19
CANT
Overweight
Marinus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros started Marinus Pharmaceuticals with an Overweight rating and $19 price target. The analyst views the stock's risk/reward as compelling into upcoming data catalysts for ganaxolone, a positive allosteric modulator of GABAA receptor.
12/10/18
JMPS
12/10/18
NO CHANGE
Target $29
JMPS
Outperform
Marinus Pharmaceuticals price target raised to $29 from $22 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Marinus Pharmaceuticals to $29 after the company announced it is advancing both ganaxolone studies into the next phase of development to evaluate IV and oral dose regimens.
12/10/18
JMPS
12/10/18
NO CHANGE
Target $29
JMPS
Outperform
JMP boosts Marinus target to $29, sees 'clear' competitor to Sage Therapeutics
JMP Securities analyst Jason Butler raised his price target for Marinus Pharmaceuticals (MRNS) to $29 from $22 after the company announced positive results for both IV and oral formulations of ganaxolone in postpartum depression. The stock in midday trading is up 1c to $5.18. The results make comparisons to Sage Therapeutics' (SAGE) brexanolone and SAGE-217 relevant, Butler tells investors in a research note. Further, the analyst sees "potentially differentiating attributes" for ganaxolone. Specifically, at 60 hours, the optimal dose cohort for the IV formulation showed a 16.9 point reduction from baseline in HAM-D, and by comparison, in its Phase 3 trial, brexanolone showed a 17.7 point to 19.9 point reduction, explains the analyst. Butler increased his probability of approval for ganaxolone in PPD to 70% from 55%. He believes this morning's results show that Marinus represents a "clear and relevant competitor" to Sage. The analyst reiterates an Outperform rating on Marinus Pharmaceuticals.
FLDM Fluidigm
$7.58

-0.11 (-1.43%)

11/02/18
PIPR
11/02/18
UPGRADE
Target $10
PIPR
Overweight
Fluidigm upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk upgraded Fluidigm to Overweight and raised his price target for the shares to $10 from $6.70. Mass Cytometry lead the beat in Q3 with both strong instrument placements and consumables growth while management remains confident on long-term adoption trends, Quirk tells investors in a post-earnings research note. The analyst is impressed with Mass Cytometry adoption and upgraded the shares to reflect that.
TOCA Tocagen
$12.85

0.2 (1.58%)

08/30/18
08/30/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PayPal (PYPL) initiated with a Buy at Berenberg. 2. Akoustis (AKTS) initiated with an Outperform at Oppenheimer. 3. Adverum Biotechnologies (ADVM) initiated with a Buy at SunTrust. 4. Tocagen (TOCA) initiated with a Buy at Chardan. 5. Tandem Diabetes (TNDM) initiated with a Buy at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/04/18
SBSH
09/04/18
INITIATION
Target $27
SBSH
Buy
Tocagen initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Tocagen with a Buy rating and $27 price target. Tocagen has an innovative treatment for high grade glioma, Karnauskas tells investors in a research note. She sees potential for 600% share upside, with downside risk of 56%, into the company's brain cancer data in the first half of 2019.
08/30/18
CHDN
08/30/18
INITIATION
Target $30
CHDN
Buy
Tocagen initiated with a Buy at Chardan
Chardan analyst Gbola Amusa started Tocagen with a Buy rating and $30 price target. The analyst cited the risk-reward proposition on its pivotal, Phase III, BTD/PRIME-designated therapy, TOCA 511 and TOCA FC, for high-grade gliomas.
09/20/18
RILY
09/20/18
NO CHANGE
Target $22
RILY
Buy
Tocagen price target raised to $22 from $15 at B. Riley FBR
B. Riley FBR analyst Madhu Kumar raised his price target for Tocagen to $22 and reiterates a Buy rating on the shares following early enrollment completion in the Phase III Toca 5 trial. The analyst views early enrollment completion as positive for the RHGG Phase III trial and increased his launch probability from 30% to 40%.
LAND Gladstone Land
$13.33

-0.16 (-1.19%)

ANGI Angi Homeservices
$16.62

-0.11 (-0.66%)

10/12/18
10/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Comcast (CMCSA) reinstated with an Overweight at JPMorgan. 2. Abeona Therapeutics (ABEO) initiated with a Buy at Mizuho. 3. Foamix (FOMX) initiated with an Overweight at Cantor Fitzgerald. 4. Match Group (MTCH) and IAC (IAC) were initiated with a Buy at Nomura Instinet while Angi Homeservices (ANGI) was initiated with a Neutral at Nomura Instinet. 5. Terex (TEX) initiated with a Neutral at Longbow. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/18
BNCH
11/09/18
NO CHANGE
Target $260
BNCH
Buy
IAC pullback presents attractive entry point, says Benchmark
Benchmark analyst Daniel Kurnos views the pullback in IAC (IAC) shares following its earnings report as an attractive entry point, stating that he sees the breaking out both Dotdash and Vimeo going forward as presenting the potential for a "cleaner" core valuation. He also sees Angi Homeservices (ANGI) having upside going forward and thinks Match (MTCH) will potentially bottom out after what he views as an overreaction to its guidance. Kurnos keeps a Buy rating on IAC shares with a $260 price target.
11/28/18
MACQ
11/28/18
INITIATION
MACQ
Outperform
Angi Homeservices initiated with an Outperform at Macquarie
11/09/18
BMOC
11/09/18
NO CHANGE
Target $282
BMOC
Outperform
IAC price target raised to $282 from $265 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on IAC (IAC) to $282 and kept his Outperform rating after its Q3 earnings beat along with strong performance coming from its ANGI Homeservices (ANGI) and Match Group (MTCH) holdings. The analyst is also positive on the improving execution of IAC'c Vimeo business, accelerating Dotdash, and more mobile-driven sales at Apalon.
BAC Bank of America
$24.58

-0.17 (-0.69%)

12/11/18
KBWI
12/11/18
DOWNGRADE
KBWI
Market Perform
Bank of America downgraded to Market Perform from Outperform at Keefe Bruyette
12/07/18
FBCO
12/07/18
NO CHANGE
Target $35
FBCO
Outperform
Bank of America price target cut to $35 from $36 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke maintained a Neutral rating on Bank of America (BAC) but cut her price target to $35 from $36. In a research note to investors, she says that she has increased the weighting on her "gray sky valuation" to 25% from 15% and reduced the weighting on her "blue sky scenario" to 25% from 35%, and while she does not anticipate an imminent turn in the cycle, she feels she must recognize some increased probability relative to the status quo. For Bank of America, she says organic revenue growth, visible operating leverage, manageable credit cost increases and capital efficiency will drive realization of franchise value. The analyst also lowered her price targets on other large banks, including Morgan Stanley (MS), PNC (PNC), State Street (STT), Goldman Sachs (GS), JPMorgan (JPM) and Wells Fargo (WFC).
12/07/18
FBCO
12/07/18
NO CHANGE
Target $146
FBCO
Neutral
PNC Financial price target cut to $146 from $150 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke maintained a Neutral rating on PNC Financial (PNC) but cut her price target to $146 from $150. In a research note to investors, she says that she has increased the weighting on her "gray sky valuation" to 25% from 15% and reduced the weighting on her "blue sky scenario" to 25% from 35%, and while she does not anticipate an imminent turn in the cycle, she feels she must recognize some increased probability relative to the status quo. The analyst also lowered her price targets on other large banks, including Morgan Stanley (MS), Bank of America (BAC), State Street (STT), Goldman Sachs (GS), JPMorgan (JPM) and Wells Fargo (WFC).
12/11/18
KBWI
12/11/18
DOWNGRADE
Target $29
KBWI
Market Perform
Bank of America downgraded to Market Perform with $29 target at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl downgraded Bank of America to Market Perform from Outperform and lowered his price target for the shares to $29 from $34. The analyst sees a lack of catalysts in 2019.
MS Morgan Stanley
$40.62

-0.07 (-0.17%)

12/11/18
KBWI
12/11/18
DOWNGRADE
Target $45
KBWI
Market Perform
Morgan Stanley downgraded to Market Perform with $45 target at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl downgraded Morgan Stanley to Market Perform from Outperform and lowered his price target for the shares to $45 from $56. The analyst sees a lack of catalysts in 2019.
12/11/18
KBWI
12/11/18
DOWNGRADE
KBWI
Market Perform
Morgan Stanley downgraded to Market Perform from Outperform at Keefe Bruyette

TODAY'S FREE FLY STORIES

XLE

Energy Select Sector SPDR

$61.79

-0.6 (-0.96%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$105.40

0.16 (0.15%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$52.42

-0.34 (-0.64%)

08:19
01/24/19
01/24
08:19
01/24/19
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

08:18
01/24/19
01/24
08:18
01/24/19
08:18
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XLU

Utilities SPDR

$53.79

0.56 (1.05%)

08:18
01/24/19
01/24
08:18
01/24/19
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$52.57

0.58 (1.12%)

08:18
01/24/19
01/24
08:18
01/24/19
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$89.55

0.07 (0.08%)

08:18
01/24/19
01/24
08:18
01/24/19
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$144.61

-0.36 (-0.25%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$245.75

1.64 (0.67%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$133.76

0.82 (0.62%)

, UNH

UnitedHealth

$267.12

1.44 (0.54%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Recommendations
HCA Healthcare, UnitedHealth, Johnson & Johnson analyst commentary  »

HCA Healthcare elevated…

HCA

HCA Healthcare

$133.76

0.82 (0.62%)

UNH

UnitedHealth

$267.12

1.44 (0.54%)

JNJ

Johnson & Johnson

$128.82

0.06 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 29

    Jan

  • 18

    Feb

  • 19

    Feb

  • 28

    May

SPY

SPDR S&P 500 ETF Trust

$263.42

0.37 (0.14%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$25.72

0.01 (0.04%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

08:17
01/24/19
01/24
08:17
01/24/19
08:17
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

SMH

Market Vectors Semiconductor

$89.82

-0.36 (-0.40%)

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

Invesco QQQ Trust

$162.20

0.04 (0.02%)

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Technical Analysis
Invesco QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

$0.00

(0.00%)

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Conference/Events
JPMorgan to hold a conference »

Thailand Conference will…

NDX

Nasdaq 100 Index

$0.00

(0.00%)

08:16
01/24/19
01/24
08:16
01/24/19
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$15.22

-0.18 (-1.17%)

08:15
01/24/19
01/24
08:15
01/24/19
08:15
Downgrade
CenturyLink rating change  »

Guggenheim says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 25

    Feb

08:15
01/24/19
01/24
08:15
01/24/19
08:15
General news
Jobless Claims to be reported at 08:30 »

Week of 1/19 Jobless…

PRTO

Proteon Therapeutics

$2.63

0.01 (0.38%)

08:14
01/24/19
01/24
08:14
01/24/19
08:14
Hot Stocks
Proteon Therapeutics announces PATENCY-1 trial results published »

Proteon Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$140.75

0.98 (0.70%)

08:14
01/24/19
01/24
08:14
01/24/19
08:14
Hot Stocks
Honeywell and Pipistrel collaborate on urban air mobility technologies »

Honeywell and Pipistrel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 13

    Feb

ESND

Essendant

$12.48

-0.08 (-0.64%)

08:13
01/24/19
01/24
08:13
01/24/19
08:13
Hot Stocks
Essendant, Staples announce extension of tender offer for Essendant shares »

Staples and Essendant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LRCX

Lam Research

$139.24

-0.58 (-0.41%)

08:13
01/24/19
01/24
08:13
01/24/19
08:13
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

VAR

Varian Medical

$126.83

1.57 (1.25%)

08:13
01/24/19
01/24
08:13
01/24/19
08:13
Recommendations
Varian Medical analyst commentary  »

Varian Medical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

  • 30

    Jan

  • 14

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.